Diadem Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

Diadem General Information

Description

Developer of a diagnostic platform designed to predict Alzheimer's disease in advance. The company's platform offers predictions, monitoring, diagnosis, and successful drug development for Alzheimer's disease, enabling patients to get treatment at a cost-effective price.

Contact Information

Website
diademdx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Via Ceresio 7
  • Milan
  • Italy
Primary Industry
Diagnostic Equipment
Corporate Office
  • Via Ceresio 7
  • Milan
  • Italy

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Diadem Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 13-Aug-2026 Completed Generating Revenue
4. Grant 07-Sep-2022 Completed Generating Revenue
3. Later Stage VC 24-Feb-2022 Completed Generating Revenue
2. Later Stage VC (Series A) 21-Dec-2018 $1.7M $1.7M Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2012 Completed Startup
To view Diadem’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Diadem Patents

Diadem Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250208143-A1 P53 fragments as markers for diagnosis and prognosis of neurodegenerative disease states Pending 22-Dec-2023
US-20260235628-A1 U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease Pending 08-Jan-2023
WO-2024148357-A2 U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease Inactive 08-Jan-2023
WO-2024148357-A3 U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease Inactive 08-Jan-2023
US-20250172555-A1 Device for detection and prognostic assessment of neurodegenerative disorders Pending 02-Aug-2022 G01N33/54388
To view Diadem’s complete patent history, request access »

Diadem Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Diadem Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Seed Healthcare Venture Capital Minority
Tech and Biomedical Foundation Venture Capital Minority
National Institute on Aging Government
CDP Venture Capital (Rome) Venture Capital Minority
Panakes Partners Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Diadem FAQs

  • When was Diadem founded?

    Diadem was founded in 2012.

  • Where is Diadem headquartered?

    Diadem is headquartered in Milan, Italy.

  • What is the size of Diadem?

    Diadem has 10 total employees.

  • What industry is Diadem in?

    Diadem’s primary industry is Diagnostic Equipment.

  • Is Diadem a private or public company?

    Diadem is a Private company.

  • What is Diadem’s current revenue?

    The current revenue for Diadem is .

  • How much funding has Diadem raised over time?

    Diadem has raised $21.5M.

  • Who are Diadem’s investors?

    Seed Healthcare, Tech and Biomedical Foundation, National Institute on Aging, CDP Venture Capital (Rome), and Panakes Partners are 5 of 6 investors who have invested in Diadem.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process